Mechanical Ventilation: A Study Notes

I. Methods of Oxygen Delivery

There are 3 main methods to deliver oxygen:

A. Non-invasive

1. Face Mask + Oxygen Source

   • Patient breathes spontaneously.

   • Machine only delivers oxygen — patient does the work of breathing.

2. CPAP or BiPAP

   • Connected to a machine that provides positive airway pressure.

   • CPAP = Continuous Positive Airway Pressure → prevents alveolar collapse by keeping pressure > 0 (e.g., +5 cmH₂O).

   • BiPAP = Two pressure levels (inspiratory and expiratory).

B. Invasive

3. Endotracheal Intubation + Mechanical Ventilation

   • Used when patient cannot maintain airway or breathe adequately.

   • Common during surgery or critical illness (e.g., respiratory failure, anesthesia).

II. CPAP vs. PEEP

Feature	CPAP	PEEP
Invasiveness	Non-invasive (mask)	Invasive (intubated)
Function	Keeps airway pressure positive	Same effect but via ventilator
Key Concept	Maintains alveolar patency; prevents collapse

III. Indications for Mechanical Ventilation

• Respiratory failure (hypoventilation, apnea)

• Airway protection during anesthesia

• Severe hypoxia or acidosis

• Cardiac arrest

• Neuromuscular paralysis (e.g., coma, overdose)

ABC Approach:

• A – Airway: Intubate if not patent

• B – Breathing: Mechanical ventilation

• C – Circulation: Manage BP, HR, fluids, inotropes (dopamine, epinephrine, etc.)

IV. Purposes of Mechanical Ventilation

• Maintain oxygenation (PaO₂)

• Control CO₂ (PaCO₂)

• Maintain pH balance

• Deliver anesthetic gases during surgery

• Prevent aspiration

V. Modes of Ventilation

1. Continuous Ventilation

• Machine does all the work (no spontaneous breathing).

• Use if patient is sedated, paralyzed, or comatose.

• Example: Assist Control (AC/CMV) = Volume control mode.

2. Intermittent Ventilation

• Allows spontaneous breaths between machine breaths.

• Example: SIMV (Synchronized Intermittent Mandatory Ventilation)
  → safer for weaning if patient can trigger own breaths.

VI. Ventilator Settings You Control

Parameter	Definition	Notes
Tidal Volume (Vt)	Volume of air per breath	Normal ~500 mL
Rate (RR)	Breaths per minute	Usually 10–18/min
FiO₂	Fraction of inspired O₂	Room air = 21%; can raise to 40–100%
PEEP	End-expiratory pressure	Keeps alveoli open
Flow Rate	Volume/time of gas delivery	Affects inspiratory time
Pressure	Inspiratory pressure limit	Used in pressure-controlled modes

VII. Example Ventilator Order

Mode: Assist-Control
RR: 14
Vt: 500 mL
FiO₂: 40%
PEEP: 5 cmH₂O

VIII. Adjustments Based on ABG

Problem	Finding	Action
Respiratory Acidosis	↑ PaCO₂, ↓ pH	↑ RR and/or ↑ Vt
Hypoxemia	↓ PaO₂	↑ FiO₂ and/or ↑ PEEP

IX. Lung Compliance

• Definition: Ease of lung expansion
  →Compliance=ΔP/ΔV​

• Low compliance: Stiff lungs (e.g., ARDS, fibrosis)

• High compliance: Floppy lungs (e.g., emphysema)

If compliance ↓:

• In volume control, pressure ↑

• In pressure control, volume ↓

• Alarm triggers when extreme.

X. Boyle’s Law in Ventilation

X. Boyle’s Law in Ventilation

$P \propto \frac{1}{V}$ (at constant temperature)

• As volume ↑ → pressure ↓ (and vice versa).

• Explains negative-pressure inspiration and mechanical ventilation dynamics

• As volume ↑ → pressure ↓ (and vice versa).

• Explains negative-pressure inspiration and mechanical ventilation dynamics.

XI. Peak vs. Plateau Pressure

Pressure Type	Represents	Increased By	Indicates
Peak Pressure	Airway resistance	Bronchospasm, mucus, kinked tube	Airway problem
Plateau Pressure	Alveolar pressure (no flow)	Pulmonary edema, ARDS, pneumothorax	↓ Lung compliance

Mnemonic:

• ↑ Peak = Airway resistance problem

• ↑ Plateau = Lung compliance problem

XII. Pulmonary vs. Alveolar Ventilation

Concept	Formula	Significance
Minute (Pulmonary) Ventilation	RR × Vt	Total air moved per minute
Alveolar Ventilation	RR × (Vt – Dead Space)	Air that actually reaches alveoli

• Shallow rapid breathing: ↓ alveolar ventilation (wasted effort).

• Deep slow breathing: ↑ alveolar ventilation (more efficient).

XIII. Dangers of Excessive Settings

Parameter	Too High → Problem
RR	Auto-PEEP (air trapping) in COPD/asthma
Vt	Barotrauma, inflammation
FiO₂	Oxygen toxicity (retinopathy in neonates, lung injury)
PEEP	↓ Venous return → ↓ Cardiac output, hypotension

XIV. PEEP in CHF

• Beneficial: ↓ Venous return → ↓ cardiac workload

• Caution: Too much → hypotension, ↓ perfusion

• Always check vitals before adjusting PEEP.

XV. Clinical Terms

Term	Meaning
Triggering the Vent	Patient initiates a breath
Riding the Vent	Machine fully controls breathing
Spontaneous RR	Patient’s own breathing frequency

XVI. Special Cases

• ARDS / Restrictive disease: ↑ PEEP, ↓ Vt

• Emphysema / Obstructive: ↑ Flow rate to allow full exhalation, avoid auto-PEEP

XVII. Complications

1. Barotrauma – alveolar rupture due to overdistention

2. Ventilator-Induced Lung Injury (VILI)

3. Ventilator-Associated Pneumonia (VAP)

XVIII. Ventilator-Associated Pneumonia (VAP)

Definition: Pneumonia occurring 48–72 hrs after intubation

Common Pathogens:

Timing	Likely Organisms	Type
≤4 days (early)	Strep. pneumoniae, H. influenzae, Klebsiella	Community-type
≥5 days (late)	Pseudomonas, MRSA, Acinetobacter	Hospital-type (drug-resistant)

Predisposing Factor:

• Malnutrition in ICU patients.

Best Diagnostic Sample:

• Protected Specimen Brush (PSB) via bronchoscopy → deep, uncontaminated sample.

Empiric Treatment:

Timing	Therapy
Early (≤4 days)	Beta-lactam + Respiratory fluoroquinolone
Late (≥5 days)	Add anti-Pseudomonal + Vancomycin/Linezolid for MRSA

Study Note: Mechanical Ventilation

1. Definition and Purpose

Mechanical ventilation (MV) is the use of a machine (ventilator) to assist or completely take over the process of breathing when a patient is unable to maintain adequate gas exchange on their own.

Purpose:

• Support oxygenation (↑ O₂ delivery to tissues)

• Support ventilation (remove CO₂)

• Decrease the work of breathing

• Allow lung protection and rest

• Facilitate recovery in severe respiratory failure or anesthesia

2. Indications for Mechanical Ventilation

A. Respiratory Failure

1. Hypoxemic (Type I) – PaO₂ < 60 mmHg on room air

   • Causes: ARDS, pneumonia, pulmonary edema, atelectasis, pulmonary embolism

2. Hypercapnic (Type II) – PaCO₂ > 45 mmHg with pH < 7.35

   • Causes: COPD, asthma, drug overdose, neuromuscular disorders, CNS depression

3. Mixed (Type III) – e.g., severe ARDS or trauma

B. Airway Protection

• Coma, head injury, drug overdose, seizures, aspiration risk

C. Surgery / Anesthesia

• For controlled ventilation during general anesthesia

D. Shock or Multiorgan Failure

• To decrease metabolic demand and oxygen consumption

3. Basic Physiology of Ventilation

Normal breathing involves negative intrathoracic pressure generated by diaphragm contraction.
Mechanical ventilation delivers positive pressure to inflate the lungs.

Goal: Maintain adequate oxygenation (PaO₂) and ventilation (PaCO₂) without causing lung injury.

4. Basic Ventilator Components

• Gas source: Oxygen and air

• Flow/pressure sensors: Measure tidal volume and airway pressures

• Valves: Control inspiration and expiration

• Humidifier: Prevents mucosal drying

• Alarms: Detect leaks, disconnections, or high pressures

5. Key Ventilator Parameters

Parameter	Definition	Normal Range / Typical Value
FiO₂	Fraction of inspired O₂	21–100%
Vt (Tidal Volume)	Volume delivered per breath	6–8 mL/kg (ideal body weight)
RR (Respiratory Rate)	Breaths per minute	12–20/min
PEEP (Positive End-Expiratory Pressure)	Pressure left in alveoli at end expiration to prevent collapse	5–10 cmH₂O (can go higher in ARDS)
PIP (Peak Inspiratory Pressure)	Maximum pressure during inspiration	< 30–35 cmH₂O
Plateau Pressure	Pressure in alveoli after inspiration (no flow)	< 30 cmH₂O
I:E Ratio	Inspiratory:Expiratory time	1:2 (normal), may be adjusted in ARDS or asthma
Minute Ventilation (Ve)	RR × Vt	5–10 L/min

6. Modes of Mechanical Ventilation

A. Controlled Modes (Full Support)

1. Volume-Controlled Ventilation (VCV)

   • Delivers set Vt regardless of pressure

   • Used in most ICU cases

   • Advantage: Predictable CO₂ removal

   • Risk: High airway pressure → barotrauma

2. Pressure-Controlled Ventilation (PCV)

   • Delivers breath until a set pressure is reached

   • Volume varies depending on compliance

   • Advantage: Limits airway pressure, protects lungs

   • Risk: Unstable tidal volume if compliance changes

B. Assisted / Supported Modes (Partial Support)

1. SIMV (Synchronized Intermittent Mandatory Ventilation)

   • Combines mandatory breaths with spontaneous ones

   • Useful during weaning

   • Can add Pressure Support (PS) for comfort

2. Pressure Support Ventilation (PSV)

   • Patient initiates every breath; ventilator assists to a preset pressure

   • No fixed rate or tidal volume

   • Used for weaning or noninvasive ventilation

3. CPAP (Continuous Positive Airway Pressure)

   • Constant positive pressure throughout breathing cycle

   • Patient breathes spontaneously

   • Used for sleep apnea and mild respiratory failure

C. Advanced / Special Modes

• BiPAP: Noninvasive; has inspiratory (IPAP) and expiratory (EPAP) pressures

• APRV (Airway Pressure Release Ventilation): For ARDS; long inspiratory phase for alveolar recruitment

• PRVC (Pressure-Regulated Volume Control): Hybrid mode; pressure adjusted automatically to deliver set Vt

7. Oxygenation vs. Ventilation

Function	Controlled By	Key Parameters
Oxygenation	FiO₂ + PEEP	↑ PEEP = ↑ alveolar recruitment
Ventilation (CO₂ removal)	RR + Vt	↑ RR or Vt → ↓ PaCO₂

8. ABG Monitoring in Ventilation

ABG Finding	Problem	Correction
↓ PaO₂	Hypoxemia	↑ FiO₂, ↑ PEEP
↑ PaCO₂	Hypoventilation	↑ RR, ↑ Vt
↓ PaCO₂	Hyperventilation	↓ RR, ↓ Vt

9. Complications of Mechanical Ventilation

A. Pulmonary

• Barotrauma: Pneumothorax from high pressures

• Volutrauma: Alveolar overdistension

• Atelectrauma: Repeated alveolar collapse and reopening

• Oxygen toxicity: From prolonged FiO₂ > 60%

• VAP (Ventilator-Associated Pneumonia)

B. Hemodynamic

• ↓ Venous return → ↓ Cardiac output → Hypotension (due to ↑ intrathoracic pressure)

C. Other

• Diaphragmatic atrophy (disuse)

• Ventilator dependence

• Tracheal injury or stenosis (from cuff pressure)

10. Lung Protective Strategy (Especially in ARDS)

Goal: Prevent ventilator-induced lung injury (VILI)

Strategy	Target
Low tidal volume	6 mL/kg (ideal body weight)
Limit plateau pressure	< 30 cmH₂O
PEEP optimization	To prevent alveolar collapse
FiO₂ titration	Keep SpO₂ 88–95%
Permissive hypercapnia	Allow mild ↑ PaCO₂ if pH > 7.2

11. Weaning from Ventilation

Readiness Criteria

• Hemodynamically stable

• Adequate oxygenation (FiO₂ ≤ 40%, PEEP ≤ 5)

• Good mental status

• Strong cough and minimal secretions

Weaning Methods

1. Spontaneous Breathing Trial (SBT):

   • CPAP or low PSV for 30–120 minutes

   • Watch RR, HR, BP, SpO₂, and effort

2. Gradual SIMV / PSV reduction

Failure Signs

• RR > 35, HR ↑ > 20%, SpO₂ < 90%, anxiety, diaphoresis, paradoxical breathing

12. Ventilator Graphics / Loops

• Pressure-time, flow-time, and volume-time waveforms help detect:

  • Leaks, asynchrony, auto-PEEP, airway resistance, and compliance changes

• Pressure-volume loops:

  • Slope = compliance

  • Hysteresis (difference between insp/exp curve)

13. Sedation and Analgesia in Ventilated Patients

• Maintain comfort and synchrony

• Common agents: Propofol, Midazolam, Fentanyl, Dexmedetomidine

• Use sedation scales (e.g., RASS)

• Perform daily sedation interruptions

14. Summary Table

Disease	Problem	Ventilation Strategy
ARDS	↓ Compliance	Low Vt, high PEEP, FiO₂ titration
COPD / Asthma	Air trapping	Low RR, long expiratory time
Neuromuscular failure	Weak effort	Full support (AC-VC or PC)
Head injury	Prevent ↑ ICP	Avoid hypercapnia (target PaCO₂ 35–40)

15. Key Concept: Cellular Respiration & Ventilation Link

• Ventilation → Brings O₂ in, removes CO₂

• Perfusion → Delivers O₂ to tissues

• Cellular respiration → Uses O₂ to produce ATP and CO₂

• If ventilation fails → CO₂ builds up → Respiratory acidosis

• If perfusion fails → Tissues shift to anaerobic metabolism → Lactic acidosis

In Summary:

Mechanical ventilation is life-saving but must be individualized. Understanding physiology, settings, and patient responses prevents complications and improves outcomes.

Study Notes: Lung Compliance and Pulmonary Mechanics

Lung Compliance — how easily the lungs expand when pressure is applied.

1. Definition of Compliance

Compliance = ΔV / ΔP
→ Change in Volume / Change in Pressure

• Describes the distensibility (expandability) of the lungs.

• High compliance = lungs expand easily.

• Low compliance = lungs are stiff and hard to expand.

Transmural (Transpulmonary) Pressure = Alveolar pressure − Intrapleural pressure
→ This is the driving pressure that expands the lungs.

2. Relationship Between Compliance, Elasticity, and Surface Tension

Concept	Function	Direction
Compliance	Allows lungs to expand	Expand
Elasticity / Recoil	Makes lungs collapse	Collapse
Surface Tension	Promotes alveolar collapse	Collapse

Opposites:

• Compliance ↔ Elasticity

• Compliance ↔ Surface tension

3. Real-Life Analogy: Socks Example

Analogy	Explanation	Disease Type
Normal Socks	Expand normally, recoil normally	Normal lung
Old socks (loose rubber band)	Easy to expand (↑ compliance), don’t recoil (↓ elasticity)	Emphysema (Obstructive)
Shrunk socks (tight)	Hard to expand (↓ compliance), strong recoil	Pulmonary Fibrosis (Restrictive)

Summary:

• Emphysema → ↑ Compliance, ↓ Recoil

• Fibrosis → ↓ Compliance, ↑ Recoil

4. Compliance vs. Recoil

Feature	Compliance	Recoil
Meaning	Lung expansion ability	Lung collapsing force
Increased in	Emphysema	Fibrosis
Decreased in	Fibrosis	Emphysema
Affected by	Surfactant, elastase	Surface tension, elastin

5. Obstructive vs Restrictive Lung Disease

Type	Problem	Example	Compliance	Key Symptom
Obstructive	Trouble getting air out	Emphysema, COPD, Asthma	↑	Air trapping
Restrictive	Trouble getting air in	Pulmonary Fibrosis	↓	Small lung volumes

Mnemonics:

• Obstructed = Out problem

• Restricted = In problem

6. Surfactant and Surface Tension

• Surface tension: Force trying to collapse alveoli.

• Surfactant (produced by Type II pneumocytes): Reduces surface tension → ↑ Compliance.

• No surfactant (e.g. neonatal RDS): ↑ Surface tension → ↓ Compliance → Lung collapse.

7. Saline-Filled vs Air-Filled Lungs

Type	Has Surface Tension?	Recoil	Compliance
Air-filled lung	Yes	High	Lower
Saline-filled lung	No	Low	Higher

Reason:
No air-fluid interface → No surface tension → Easier expansion (↑ compliance).
Therefore, saline-filled lungs have greater compliance.

8. Expiration vs Inspiration Compliance

• Expiration curve has greater compliance than inspiration.

Why?

• During inspiration, surface tension must be overcome → requires more pressure.

• During expiration, alveoli are already open → less pressure needed.

Proof (3 methods):

1. At same pressure, expiratory volume > inspiratory volume → ↑ compliance.

2. At same volume, expiration requires less pressure.

3. Graph slope (ΔV/ΔP) steeper in expiration → ↑ compliance.

9. Alpha-1 Antitrypsin Deficiency

• Mechanism:
  ↓ Alpha-1 antitrypsin → ↑ Elastase activity → destroys elastin → ↓ Recoil → ↑ Compliance

• Effect:
  Easy to inhale (air in), hard to exhale (air trapped) → Obstructive pattern

10. Pressure–Volume Loops

• Plot Volume (Y-axis) vs Pressure (X-axis)

• Used to compare:

  • Normal lung

  • Emphysematous lung (↑ slope = ↑ compliance)

  • Fibrotic lung (↓ slope = ↓ compliance)

Slope = Compliance = ΔV / ΔP
→ Steeper slope = higher compliance.

11. Chest Wall vs Lung Compliance

• Chest wall naturally expands outward.

• Lungs naturally recoil inward.

• Together, they balance to create a negative intrapleural pressure.

• The combined compliance (lung + chest wall) is less than either alone.

12. Quick Summary Table

Parameter	Emphysema (Obstructive)	Fibrosis (Restrictive)
Compliance	↑ Increased	↓ Decreased
Recoil	↓ Decreased	↑ Increased
Air In (Inspiration)	Easy	Difficult
Air Out (Expiration)	Difficult	Easy
Elastic Tissue	Destroyed (↓ elastin)	Excess collagen
Example Analogy	Old socks	Shrunk socks

13. Key Equations and Takeaways

• Compliance = ΔV / ΔP

• Inverse Relationship: Compliance ↔ Recoil

• Surfactant ↓ surface tension → ↑ Compliance

• Obstructive = outflow problem (↑ compliance)

• Restrictive = inflow problem (↓ compliance)

14. Case Example

Three subjects (A, B, C):

1. Normal lung → moderate compliance

2. Emphysema → high compliance

3. Amiodarone/Bleomycin (fibrosis) → low compliance

15. Key Quote

“The negative intrapleural pressure is due to the dynamic harmonious antagonism between the chest wall (expands) and the lung (recoils).”

Core Memory Aids

• Right = Release (O₂ curve mnemonic from previous lesson)

• Compliance = Expand

• Elasticity = Recoil

• Obstructive → Out problem

• Restrictive → In problem

Study Notes: Oxygen Content, Saturation, and Hemoglobin Physiology

This section is into understanding oxygen physiology, because disorders of oxygen content and saturation often accompany hematologic conditions.

1. Oxygen Pathway in the Body

1. Inhalation:
   Air (21% oxygen) enters the lungs.

2. Gas Exchange:
   Oxygen diffuses from alveoli → arterial blood → hemoglobin (Hb).

3. Tissue Delivery:
   Hemoglobin releases oxygen → tissues → mitochondria for oxidative phosphorylation (ATP production).

4. Carbon Dioxide (CO₂) Removal:

   • CO₂ produced during metabolism returns to blood.

   • Travels as carbaminohemoglobin to lungs.

   • Exhaled during respiration.

2. Oxygen Terms & Symbols

Term	Symbol	Meaning
Fraction of Inspired Oxygen	FiO₂	% of oxygen in inhaled air (≈ 21% or 0.21)
Alveolar Oxygen Pressure	PAO₂	Partial pressure of O₂ in the alveoli
Arterial Oxygen Pressure	PaO₂	Partial pressure of O₂ in arterial blood (≈ 95–100 mmHg)
Oxygen Saturation	SaO₂	% of hemoglobin bound to oxygen (≈ 97%)

Key Point:
For oxygen to move from alveoli to blood, a pressure gradient must exist (PAO₂ > PaO₂).

3. Hemoglobin and Oxygen Saturation

• SaO₂ (Hemoglobin Oxygen Saturation):
  % of hemoglobin molecules carrying oxygen.
  “The oxygen that’s on the hemoglobin.”

• Normal: ~97%
  Problem threshold: <93% (detected with pulse oximeter)

• Measurement:

  • ABG (Arterial Blood Gas): Measures PaO₂ and SaO₂ directly.

  • Venous samples do not reflect true oxygenation levels.

4. Oxygen Content (CaO₂)

Definition:
The total amount of oxygen in the blood (both bound and dissolved).

Components:

1. Hemoglobin concentration (amount of Hb available to carry O₂)

2. Oxygen bound to hemoglobin (SaO₂)

3. Oxygen dissolved in plasma (PaO₂)

Formula (conceptual):

O₂ Content = (Hb × 1.34 × SaO₂) + (0.003 × PaO₂)

5. Oxygen Content in Anemia

• Anemia: ↓ Red cell mass → ↓ Hemoglobin concentration

• Effects:

  • PaO₂: Normal (oxygen in plasma unaffected)

  • SaO₂: Normal (each Hb still fully saturated)

  • O₂ Content: Decreased (fewer Hb molecules overall)

Example:
If Hb is low, O₂ content drops even though pulse oximeter shows 97%.
This explains why an anemic patient can appear “normal” on pulse oximetry but still have poor oxygen delivery.

6. Oxygen–Hemoglobin Dissociation Curve

• Y-axis: SaO₂ (% saturation)

• X-axis: PaO₂ (mmHg)

At the lungs:
Oxygen binds to Hb → ↑ PaO₂, ↑ SaO₂

At the tissues:
Oxygen leaves Hb → ↓ PaO₂, ↓ SaO₂

The curve is S-shaped due to cooperative binding between oxygen molecules.

7. Curve Shifts

Right Shift

→ Hb releases oxygen more easily (to tissues)

Cause	Explanation
↑ H⁺ (↓ pH, acidosis)	Bohr effect
↑ Temperature	Fever, exercise
↑ 2,3-BPG	Chronic hypoxia, altitude
↑ CO₂	Hypercapnia

Mnemonic: “Right = Release” (right hand gives oxygen to tissues)

Left Shift

→ Hb holds onto oxygen (less release to tissues)

Cause	Explanation
↓ H⁺ (↑ pH, alkalosis)	Opposite of Bohr effect
↓ Temperature	Hypothermia
↓ 2,3-BPG	Fetal hemoglobin, stored blood
Methemoglobin, HbF	Stronger oxygen affinity

Mnemonic: “Left = Left behind” (oxygen stays on Hb; tissue left behind)

8. Clinical Case (Methemoglobinemia)

Case Summary:

• 31-year-old man treated with lidocaine for sore throat

• Returns with dusky skin, blue lips, headache, fatigue

• Low SaO₂ but PaO₂ normal or high

Diagnosis:
Methemoglobinemia — Iron in Hb oxidized to Fe³⁺ form, which cannot bind oxygen properly.
Blood appears dark brown; pulse oximetry shows low saturation despite normal PaO₂.

9. Key Takeaways

• FiO₂: Oxygen entering the body (21%)

• PaO₂: Oxygen dissolved in plasma

• SaO₂: Oxygen bound to hemoglobin

• O₂ Content: Total oxygen carried in the blood

• Anemia: Normal saturation, but low O₂ content

• Right shift: Easier O₂ delivery

• Left shift: Harder O₂ delivery

Summary:

Concept	Increased	Decreased	Result
pH (↑, alkalosis)	Left shift		↓ O₂ delivery
pH (↓, acidosis)		Right shift	↑ O₂ delivery
Temperature ↑	Right shift		↑ O₂ release
2,3-BPG ↑	Right shift		↑ O₂ release
HbF, MetHb	Left shift		↓ O₂ release
Anemia	↓ O₂ content	Normal SaO₂	↓ O₂ delivery

Field Note October 31st 2025

Case 1: 

75-year-old male with COVID, T2DM, and generalized weakness

Situation

Patient admitted from ED for generalized weakness and fatigue; found with hypoglycemia and COVID positive with symptoms.

Background

PMH: Bullous pemphigoid (on MTX), prostate cancer, insulin-dependent T2DM, HTN.

Home meds: Novolog 18 U before meals, Tresiba 46 U daily.
Recent HbA1C 10.2% (poor control).

Assessment

• Weakness likely due to acute viral infection (COVID-19) and chronic hyperglycemia.

• No SOB or hypoxia (so no steroid indication). But intermittent coughs. 

• Glucose 230–300 mg/dL; persistent poor control.

• Complains of heartburn and indigestion; no alarm symptoms.

Recommendations

1. COVID-19 / General Weakness

• Symptomatic management and PT evaluation → supports recovery and preserves mobility.

• Paxlovid initiation → started because symptoms < 5 days and high-risk comorbidities; decreases risk of progression to severe disease.
  Rationale: Early antiviral use in high-risk adults lowers hospitalization risk.

2. Diabetes Management

• Repeat HbA1C → reassess long-term glycemic control.

• Reduce Tresiba to 35 U and add lispro 5 U with meals → prevents hypoglycemia while adjusting to inpatient caloric intake.

• MDSSI coverage → allows titration per glucose trends.
  Rationale: Tight glycemic monitoring during infection prevents further weakness and dehydration.

3. Heartburn / Indigestion

• Famotidine trial and Maalox PRN → symptomatic acid control.

• H. pylori stool antigen → rule out infection as a chronic cause.

• Follow-up with PCP and possible GI referral for EGD → appropriate if persistent symptoms.
  Rationale: GERD and gastritis are common in diabetics and long-term medication users.

4. BPH

• Continue Tamsulosin 0.8 mg daily → maintains urinary flow.

General Care

• Cardiac carb-consistent diet → supports glucose and BP control.

• DVT prophylaxis (enoxaparin) → immobility and infection increase clot risk.

• Stress ulcer prophylaxis (famotidine) → prevents GI bleeding during acute illness.

• PT evaluation → determines discharge readiness and functional status.

Case 2: 

82-year-old female with constipation, UTI, and recent stroke

Situation

Readmitted from rehab two days post-discharge for LLQ pain, found to have stool impaction and E. faecalis UTI.

Background

PMH: Dementia, aortic valve stenosis s/p replacement, atrial fibrillation (on dabigatran), mitral valve prolapse, HFpEF, CAD, recent stroke.

Assessment

• LLQ pain resolved with bowel regimen.

• Completed 3-day Ampicillin for E. faecalis cystitis.

• A-fib controlled with diltiazem/metoprolol.

• Mild delirium; no acute new deficits.

• Hypokalemia, hyponatremia noted.

Recommendations

1. Constipation Management

• Continue laxatives/enemas PRN → prevents recurrence and reduces delirium risk.
  Rationale: Constipation is a frequent cause of pain and confusion in elderly post-stroke patients.

2. UTI (E. faecalis)

• Complete antibiotic course → ensure bacterial clearance.
  Rationale: Prevents ascending infection and delirium exacerbation.

3. Atrial Fibrillation / Stroke History

• Continue dabigatran 150 mg BID, aspirin 81 mg, diltiazem, metoprolol, rosuvastatin → maintain rate control, anticoagulation, and vascular protection.

• Monitor HR, BP, hydration status → avoid hypotension and dehydration.
  Rationale: Stroke prevention and cardiac stabilization are key post-event.

4. Encephalopathy / Delirium

• Reorient frequently, optimize sleep and hydration, treat reversible causes (UTI, constipation, electrolyte imbalance).
  Rationale: Elderly with dementia and stroke history are highly prone to delirium; early recognition prevents decline.

5. Hypokalemia / Electrolyte disturbances

• Monitor BMP daily; replace K⁺/Mg²⁺ as needed.
  Rationale: Electrolyte imbalances worsen arrhythmias and confusion.

General Care

• Nutrition supplements and regular diet → prevent malnutrition.

• DVT prophylaxis maintained.

• PT/OT for rehab; discharge to acute rehab → improves post-stroke recovery.

Medication Review and Analysis

1. Aspirin 81 mg (Held)

Indication: Secondary prevention of cardiovascular or cerebrovascular events (MI, stroke).
MOA: Irreversibly inhibits COX-1 and COX-2 → decreases thromboxane A₂ → inhibits platelet aggregation.
Side effects:

• GI bleeding, peptic ulcers

• Bruising, increased bleeding risk (especially with anticoagulants)

• Renal impairment with chronic use
  Interactions:

• Heparin + Aspirin → additive bleeding risk

• NSAIDs may reduce aspirin’s antiplatelet effect

Rationale for Hold: Likely due to concurrent heparin infusion (high bleeding risk).

2. Calcium-Vitamin D (Held)

Indication: Osteoporosis prevention or correction of deficiency.
MOA:

• Calcium: bone mineralization

• Vitamin D: increases intestinal absorption of calcium and phosphate
  Side effects:

• Constipation

• Hypercalcemia (esp. if on thiazides)
  Interactions:

• Can decrease absorption of some antibiotics (e.g., ceftriaxone not affected IV, but oral quinolones/tetracyclines are)

• No significant issue in this regimen.
  Rationale for Hold: Possibly NPO status or to reduce pill burden.

3. Ceftriaxone 1 g IV Q24H

Indication: Empiric antibiotic for pneumonia, UTI, sepsis, etc.
MOA: 3rd-gen cephalosporin; inhibits bacterial cell wall synthesis.
Side effects:

• Diarrhea, biliary sludging

• Hypersensitivity (esp. with penicillin allergy)

• Rare: hemolysis, elevated LFTs
  Interactions:

• Calcium-containing solutions → precipitate risk (avoid co-admin with calcium IV products).

• Minimal interaction with heparin or cardiac meds.

4. Cyanocobalamin (Vitamin B12) (Held)

Indication: Treatment/prevention of B12 deficiency or pernicious anemia.
MOA: Cofactor for DNA synthesis and neurologic function.
Side effects:

• Rare: rash, mild diarrhea
  Interactions:

• Minimal clinically significant ones.
  Rationale for Hold: Non-urgent supplement; possibly held due to swallowing difficulty or NPO.

5. Dabigatran 75 mg BID (Held)

Indication: Stroke prevention in atrial fibrillation, DVT/PE prophylaxis.
MOA: Direct thrombin (Factor IIa) inhibitor.
Side effects:

• Major bleeding (GI, intracranial)

• Dyspepsia
  Interactions:

• Heparin + Dabigatran = contraindicated (massive bleeding risk)

• P-gp inhibitors (e.g., diltiazem) ↑ dabigatran levels
  Rationale for Hold: Overlapping anticoagulation with heparin → high bleeding risk.

6. Diltiazem CD 180 mg (Held)

Indication: Rate control in atrial fibrillation, hypertension, angina.
MOA: Calcium channel blocker; decreases AV nodal conduction.
Side effects:

• Bradycardia, hypotension

• Edema, constipation
  Interactions:

• Additive bradycardia with metoprolol

• Increases dabigatran levels (P-gp inhibition)
  Rationale for Hold: Likely due to low HR, hypotension, or IV rate control switch.

7. Furosemide 40 mg (Held)

Indication: CHF, pulmonary edema, volume overload.
MOA: Loop diuretic; inhibits Na⁺/K⁺/2Cl⁻ transporter in ascending loop of Henle → natriuresis.
Side effects:

• Hypokalemia, dehydration

• Ototoxicity (high doses)

• Hypotension
  Interactions:

• Can worsen renal function when combined with nephrotoxic drugs or dehydration

• Heparin → no direct interaction, but volume depletion can increase risk of thrombosis
  Rationale for Hold: Volume status concerns (low BP, risk of dehydration).

8. Metoprolol Tartrate 5 mg IV Q6H (Held)

Indication: Rate control (A-fib), hypertension, CHF, post-MI management.
MOA: Beta-1 blocker → reduces HR, BP, and myocardial oxygen demand.
Side effects:

• Bradycardia, hypotension

• Fatigue, confusion in elderly
  Interactions:

• Additive bradycardia with diltiazem

• Masks hypoglycemia symptoms if diabetic
  Rationale for Hold: Overlap with diltiazem or low BP/HR.

9. Multivitamin with Folic Acid (Held)

Indication: Nutritional support, anemia prevention.
MOA: Vitamin replacement for metabolism and RBC synthesis.
Side effects: Minimal.
Interactions: None significant.

10. Rosuvastatin 10 mg (Held)

Indication: Hyperlipidemia, ASCVD prevention.
MOA: HMG-CoA reductase inhibitor → lowers LDL and triglycerides.
Side effects:

• Myopathy, rhabdomyolysis

• Liver enzyme elevation
  Interactions:

• Diltiazem can increase statin levels → myopathy risk

• Caution in elderly, renal impairment
  Rationale for Hold: Transient LFT issues, infection, or polypharmacy risk.

11. Heparin Infusion (Active)

Indication: Anticoagulation for atrial fibrillation, DVT/PE, or bridging therapy.
MOA: Enhances antithrombin III → inhibits thrombin and Factor Xa.
Side effects:

• Major bleeding

• Heparin-induced thrombocytopenia (HIT)
  Interactions:

• With aspirin or dabigatran → additive bleeding

• With ceftriaxone → minor bleeding risk (platelet inhibition)
  Monitoring: aPTT, platelets, bleeding signs.

High-Risk Interactions and Cautions

Combination	Risk	Mechanism / Concern
Heparin + Aspirin	🚨 High bleeding risk	Dual anticoagulant effect
Heparin + Dabigatran	🚨 Contraindicated	Additive anticoagulation
Diltiazem + Metoprolol	⚠️ Bradycardia, heart block	AV nodal suppression
Diltiazem + Dabigatran	⚠️ Increased dabigatran levels	P-gp inhibition
Diltiazem + Rosuvastatin	⚠️ Myopathy risk	Increased statin level
Furosemide + Elderly	⚠️ Dehydration, hypotension	Volume depletion
Ceftriaxone + Calcium (IV)	⚠️ Precipitate risk	Avoid co-administration

Summary Impression

This frail 83-year-old patient has polypharmacy with overlapping cardiovascular and anticoagulant therapies.
Most medications are appropriately held due to:

• High bleeding risk (heparin + other anticoagulants)

• Potential for bradycardia and hypotension (metoprolol + diltiazem)

• Renal and hepatic caution (statin, diuretic)

• Decreased oral tolerance (frailty, reduced participation)

Case 3: 

71-year-old male with COPD, A-fib, and diabetic foot infection

Situation

Admitted with fever and respiratory distress; found to have suspected LLE osteomyelitis and COPD exacerbation.

Background

PMH: COPD with chronic respiratory failure (2 L O₂, BiPAP at night), A-fib on apixaban, DM2, HTN, stroke history, chronic pain, fibromyalgia.

Assessment

• Left foot digital ulcers with exposed bone → likely osteomyelitis.

• Afebrile now, but elevated CRP.

• Cannot undergo MRI (non-compatible device).

• Stable respiratory status on home O₂ and BiPAP.

Recommendations

1. Diabetic Foot Wound / Suspected Osteomyelitis

• Continue cefazolin + metronidazole → broad coverage per diabetic foot pathway.

• Daily wound care (Betadine DSD) and offload both legs → prevents further tissue injury.

• Follow podiatry, vascular, and limb salvage team; angiography planned.
  Rationale: Multidisciplinary management is crucial to prevent amputation and systemic sepsis.

2. COPD Exacerbation / Chronic Respiratory Failure

• Continue O₂ 1–2 L and nocturnal BiPAP, inhaled budesonide, and scheduled bronchodilators.

• Completed steroid burst → reduced airway inflammation.
  Rationale: Prevents hypercapnia and supports baseline oxygenation.

3. Anticoagulation

• Hold apixaban per vascular request → minimize bleeding risk during angiography.
  Rationale: Balances thromboembolic risk versus procedural safety.

4. Cardiac and Volume Management

• Monitor BNP, resume torsemide as tolerated → treat HFpEF while avoiding dehydration.

5. Pancytopenia

• Continue monitoring CBC; no current evidence of marrow failure.
  Rationale: Infection and chronic disease may contribute; trending avoids missed progression.

General Care

• Clear liquid diet pre-procedure.

• DVT prophylaxis → apixaban or alternative per hold status.

• Monitor for hypokalemia, hypocalcemia → replace as indicated.

Case 4: 

63-year-old male with right-hand post-surgical infection

Situation

Presented with swelling and redness of the right hand after leaving AMA post-amputation for osteomyelitis and stopping antibiotics early.

Background

PMH: Uncontrolled T2DM, HTN, bipolar disorder, alcohol use disorder, prior osteomyelitis.
Surgery: Right middle finger distal phalanx amputation (this month).

Assessment

• Post-surgical wound infection due to poor antibiotic adherence.

• No systemic fever yet, but local inflammation and swelling suggest recurrence.

Recommendations

1. Infection Control

• Restart IV antibiotics per ID (Cephalexin IV, then Bactrim PO if sensitive).

• Wound cultures → confirm organism.

• Daily wound care and hand elevation.
  Rationale: Early reinitiation of therapy prevents spread to bone or sepsis.

2. Diabetes Management

• Optimize insulin regimen and monitor glucose → hyperglycemia delays wound healing.
  Rationale: Tight glucose control reduces infection recurrence.

3. Pain Management

• Tylenol PRN, avoid NSAIDs if renal function impaired.
  Rationale: Adequate analgesia promotes compliance and rest.

4. Psychiatric & Social Factors

• Address non-compliance and alcohol use with social work and psych consult.
  Rationale: Behavioral instability contributes to repeated AMA discharges.

General Care

• Monitor for systemic infection signs.

• Reinforce wound dressing and hygiene education.

Case 5: 

54-year-old female with PSUD and lumbosacral discitis/osteomyelitis

Situation

Admitted for bacteremia and spinal infection secondary to IVDU; under prolonged IV antibiotics.

Background

PMH: Polysubstance use disorder, Serratia marcescens bacteremia, L4–S1 discitis/osteomyelitis with epidural and psoas abscess, anemia, thrombocytosis.

Assessment

• On ceftriaxone 2 g IV daily (9/26–11/6).

• No neurological deficits; pain managed.

• TLSO brace when out of bed; neuro checks q8h.

• ID, neurosurgery, addiction medicine involved.

Recommendations

1. Infection / Antibiotic Therapy

• Continue ceftriaxone until 11/6 with weekly labs (CBC, BMP, LFTs, ESR, CRP).
  Rationale: Prolonged therapy required for vertebral osteomyelitis to prevent relapse.

• Repeat MRI 6–8 weeks post-therapy → assess healing and resolution.

2. Pain Management

• Tylenol, ibuprofen, flexeril, lidocaine patch, gabapentin.

• Suboxone for IVDU and pain control (declined dose increase).
  Rationale: Multimodal analgesia avoids opioids while addressing chronic pain.

3. Substance Use Disorder

• Continue suboxone and consider LAI buprenorphine at discharge.
  Rationale: Reduces relapse and improves adherence to medical therapy.

4. Anemia and Thrombocytosis

• Monitor CBC; consider iron after infection clears.
  Rationale: Anemia of chronic disease vs. mild iron deficiency likely; iron given after infection resolution to avoid bacterial proliferation.

5. Skin Care

• Hydrocortisone for eczema plaques → symptomatic relief..

6. Trichomonas Vaginitis

• Completed Flagyl course; test of cure ≥ 3 weeks post-therapy.

General Care

• Regular diet, DVT prophylaxis with Lovenox.

• Full code.

• Inpatient stay until antibiotic completion.